Sanofi has been involved in a series of strategic collaborations and innovations, demonstrating a substantial current and future role in the biotech market. Crucial updates include a health equity advancement initiative with
NAACP, an expanded collaboration with
Mirecule for Facioscapulohumeral Muscular Dystrophy (FSHD), and support for films highlighting rare blood disorders. It also opened an innovation centre in
China.
Sanford C. Bernstein upgraded Sanofi's designation to a 'strong buy', and the company saw significant
investment from Hudson Bay Capital Management. Major collaborations include a $1.5B global licensing deal with
Sino Biopharm and agreement with
EMS to sell generics manufacturer Medley.
Belén Garijo, announced as new CEO, has ambitious growth plans for Sanofi. However, some recent decisions and developments have raised concerns. Sanofi backed out from developing an mRNA flu vaccine while also facing headwinds from US policy shifts that could affect vaccine sales. Legal action from Texas alleges 'bribing' providers to boost drug prescriptions, and it has faced criticism from the Prescription Medicines Code of Practice Authority (PMCPA) in the UK. Despite these challenges, the company continues its growth strategy with transactions including a $2.2 billion deal with
Dynavax to advance adult vaccines.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 21 Mar 2026 11:45:33 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor 2
